Effects of systemic prostaglandin E1 on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. 1998

A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
Dipartimento di Medicina Interna, Cardioangiologia, Epatologia, Università di Bologna, Policlinico S. Orsola, Italy.

Prostaglandins of the E (PGE) series have long been considered "catabolic" hormones, but recent data suggest that they may be secreted in critically ill patients to counteract stress hormones, stimulating protein synthesis. Their use is under scrutiny to improve hepatic microcirculation and as cytoprotective agents. We tested the effects of PGE1 on hepatic and whole-body nitrogen metabolism in eight patients with cirrhosis. Urea-nitrogen synthesis rate, alpha-amino-nitrogen levels, and nitrogen exchange were measured in the basal, postabsorptive state and in response to continuous alanine infusion, in paired experiments, during superinfusion of PGE1 or saline. Splanchnic and systemic hemodynamics were assessed by echo-Doppler at the beginning and at the end of each experiment. PGE1 produced a rapid fall in plasma amino acids and in urea-nitrogen synthesis rate, as well as a positive nitrogen exchange. The slope of the regression of alpha-amino-nitrogen levels on urea-nitrogen synthesis rate, a measure of liver cell metabolic activity, was not affected, but the regression line was shifted rightward, suggesting a nitrogen-sparing effect of PGE1. Mesenteric artery and portal flow were unchanged, whereas femoral artery flow increased by 30%. Insulin and glucagon levels were not systematically different. We conclude that PGE1 reduces hepatic urea synthesis rate, independent of hormones and/or hepatic flow, possibly acting at the peripheral level on amino acid transport, thus reducing amino acid supply to the liver. The resulting net nitrogen sparing might be the basis for the beneficial effect of PGE1 in clinical hepatology.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009584 Nitrogen An element with the atomic symbol N, atomic number 7, and atomic weight [14.00643; 14.00728]. Nitrogen exists as a diatomic gas and makes up about 78% of the earth's atmosphere by volume. It is a constituent of proteins and nucleic acids and found in all living cells.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000527 Alprostadil A potent vasodilator agent that increases peripheral blood flow. PGE1,Prostaglandin E1,Caverject,Edex,Lipo-PGE1,Minprog,Muse,PGE1alpha,Prostaglandin E1alpha,Prostavasin,Prostin VR,Prostine VR,Sugiran,Vasaprostan,Viridal,Lipo PGE1
D000596 Amino Acids Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. Amino Acid,Acid, Amino,Acids, Amino
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol

Related Publications

A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
June 1990, Hepatology (Baltimore, Md.),
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
April 1990, Klinische Wochenschrift,
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
January 1989, VASA. Supplementum,
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
February 1985, Gastroenterology,
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
March 1982, Clinical science (London, England : 1979),
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
January 1973, Pharmacology,
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
February 2001, Metabolism: clinical and experimental,
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
October 2001, Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University,
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
June 1974, Prostaglandins,
A Fabbri, and G Bianchi, and M Brizi, and E Bugianesi, and D Magalotti, and M Zoli, and G Marchesini
August 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie,
Copied contents to your clipboard!